To understand the molecular basis of EMH, we exploited a MF mouse model obtained through the administration of a TPO‐RA, Romiplostim (Nplate) [19, 23] (Figure 1a), which develops a sizable splenomegaly in 14 days (Figure 1b, Figure S1). Here, TPO is linked to Splenomegaly.